z-logo
Premium
CD31 + Naïve Th Cells Are Stable during Six Months Following Kidney Transplantation: Implications for Post‐transplant Thymic Function
Author(s) -
Nickel Peter,
Kreutzer Stephanie,
Bold Gantuja,
Friebe Astrid,
Schmolke Kathrin,
Meisel Christian,
Jurgensen Jan Steffen,
Thiel Andreas,
Wernecke KlausDieter,
Reinke Petra,
Volk HansDieter
Publication year - 2005
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2005.00924.x
Subject(s) - immunosuppression , medicine , transplantation , kidney transplantation , cd31 , kidney , uremia , immunology , endocrinology , urology , angiogenesis
Little is known about thymus function in transplant patients. Until recently, the phenotype of T cells that recently emigrated the thymus was unknown. Now it has been demonstrated that CD4 + recent thymus emigrants coexpress CD31 and CD45RA. Here, we investigated whether uremia and immunosuppression influence CD31 + CD45RA + Th cells before and after kidney transplantation, respectively. Forty‐eight renal transplant patients were included receiving either standard triple/quadruple (n = 35) immunosuppression, OKT‐3 induction (n = 7) or FTY‐720 (n = 6), respectively. Peripheral CD31 + CD45RA + Th cells were quantified flowcytometrically before and at week 1, 4, 12 and 24 post‐transplantation. Thirty‐nine healthy adults served as controls. CD31 + CD45RA + Th cells correlated inversely with age in patients and controls and were comparable in patients before transplantation and age‐matched controls. Importantly, CD31 + CD45RA + Th cell frequencies remained stable during 6 months post‐transplantation. In conclusion, CD31 + CD45RA + Th cells are not significantly altered by uremia before and during 6 months of immunosuppressive therapy after kidney transplantation. Implications for thymus function are discussed.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here